308 related articles for article (PubMed ID: 28459498)
1. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
2. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
Seemann L; Padala SA; Mohammed A; Belayneh N
J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
[TBL] [Abstract][Full Text] [Related]
7. Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia.
Tella SH; Amalou H; Wood BJ; Chang R; Chen CC; Robinson C; Millwood M; Guthrie LC; Xu S; Levy E; Krishnasamy V; Gafni RI; Collins MT
J Bone Miner Res; 2017 Nov; 32(11):2248-2256. PubMed ID: 28718983
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.
Hu FK; Yuan F; Jiang CY; Lv DW; Mao BB; Zhang Q; Yuan ZQ; Wang Y
Chin J Cancer; 2011 Nov; 30(11):794-804. PubMed ID: 22035861
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced osteomalacia.
Florenzano P; Gafni RI; Collins MT
Bone Rep; 2017 Dec; 7():90-97. PubMed ID: 29021995
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
11. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.
Higley M; Beckett B; Schmahmann S; Dacey E; Foss E
Skeletal Radiol; 2015 Dec; 44(12):1825-31. PubMed ID: 26341245
[TBL] [Abstract][Full Text] [Related]
12. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
Boland JM; Tebben PJ; Folpe AL
J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
[TBL] [Abstract][Full Text] [Related]
13. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery.
Elston MS; Stewart IJ; Clifton-Bligh R; Conaglen JV
Bone; 2007 Jan; 40(1):236-41. PubMed ID: 16982223
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
15. Tumour-induced osteomalacia.
Minisola S; Peacock M; Fukumoto S; Cipriani C; Pepe J; Tella SH; Collins MT
Nat Rev Dis Primers; 2017 Jul; 3():17044. PubMed ID: 28703220
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report.
Ryhänen EM; Schalin-Jäntti C; Matikainen N
Front Endocrinol (Lausanne); 2021; 12():686135. PubMed ID: 34149623
[TBL] [Abstract][Full Text] [Related]
17. Tumor localization and biochemical response to cure in tumor-induced osteomalacia.
Chong WH; Andreopoulou P; Chen CC; Reynolds J; Guthrie L; Kelly M; Gafni RI; Bhattacharyya N; Boyce AM; El-Maouche D; Crespo DO; Sherry R; Chang R; Wodajo FM; Kletter GB; Dwyer A; Collins MT
J Bone Miner Res; 2013 Jun; 28(6):1386-98. PubMed ID: 23362135
[TBL] [Abstract][Full Text] [Related]
18. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
19. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
20. Tumour-induced osteomalacia: An emergent paraneoplastic syndrome.
Alonso G; Varsavsky M
Endocrinol Nutr; 2016 Apr; 63(4):181-6. PubMed ID: 26718193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
